% 0期刊文章% Shayma阿里%詹姆斯·斯坦利% Ngaire基南苏珊戴维斯% % Ingrid艾琳雅伯% Grant Sadleir Lynette % T治疗癫痫流行病学在新西兰儿童% B关注种族% D R 10.1212 / WNL 2021%。0000000000012784 % J首页神经病学% P e1933-e1941 % V 97% N 19% X背景和目标来确定周期治疗癫痫的患病率和发病率新西兰儿童群体的关注种族和社会经济地位。这是一个回顾性队列研究方法。新西兰制药收集数据库寻找个人≤18岁分发一个抗癫痫药物(ASM)从2015年的区域捕捉新西兰儿童人口的48%。综述了医疗记录确认的情况下确定的指示ASM处方。人口数据来自新西兰2013年的人口普查。结果共有3557名asm规定在2015年的2594名儿童,其中有1717(66%)儿童癫痫。表明处方被确定为3332/3557 (94%)asm。期治疗癫痫患病率为3.4每1000名儿童。最贫困地区儿童的1.9倍的速度治疗癫痫(95%可信区间[CI] 1.6 - -2.2),那些来自最贫困地区。大多数民族的患病率是类似的(欧洲/其他:3.7,95% CI 3.4 - -3.9;太平洋人民:3.6,95% CI 3.2 - -4.1; Māori: 3.4, 95% CI 3.1–3.8) apart from Asians, who had a lower prevalence of 2.3 per 1,000 (95% CI 2.0–2.6). However, when adjusted for socioeconomic deprivation, the prevalence of epilepsy was highest in European and similar in Māori, Pacific, and Asian children.Discussion This is the largest pediatric epidemiology epilepsy study where diagnosis of epilepsy was confirmed by case review. This is the first study to provide epidemiologic information for pediatric epilepsy in Māori and Pacific children.ASM=antiseizure medication; CI=confidence interval; DHB=District Health Board; MELAA=Middle Eastern/Latin American/African; NHI=National Health Index; NZDep=New Zealand index of deprivation %U //www.ez-admanager.com/content/neurology/97/19/e1933.full.pdf